Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 1.00 |
| ▸ | DRD3 | P35462 | 7/20 | 1.00 |
| ▸ | HTR1A | P08908 | 7/20 | 1.00 |
| ▸ | DRD4 | P21917 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | HTR3A | P46098 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.46 |
| ▸ | HTR3B | O95264 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29799509 | 1.00 | DRD2 (1.00) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL23637606 | 0.91 | DRD2 (0.83) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL14397163 | 0.85 | HTR1A (0.74) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL27635353 | 0.85 | HTR1A (0.74) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL31561598 | 0.84 | HTR1A (0.73) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL335802 | 0.84 | HTR1A (0.73) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL28078181 | 0.84 | HTR1A (0.73) | DRD2DRD3HTR1ADRD4HTR2A | |
| Hydrochloric Acid SCHEMBL27635338 | 0.84 | HTR1A (0.72) | DRD2DRD3HTR1ADRD4HTR2A | |
| Hydrochloric Acid SCHEMBL7982587 | 0.83 | HTR1A (0.71) | DRD2DRD3HTR1ADRD4HTR2A | |
| Hydrochloric Acid SCHEMBL7927336 | 0.83 | HTR1A (0.71) | DRD2DRD3HTR1ADRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594294-A1 | DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-3848351-B1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | US HEALTH (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240408084-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-12-12 | — | — | US | disclosed |
| US-12162861-B2 | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-12-10 | — | — | US | disclosed |
| US-12097196-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-09-24 | — | — | US | disclosed |
| WO-2024072930-A1 | DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2022187206-A1 | DUAL-TARGET MU OPIOID AND DOPAMINE D3 RECEPTORS LIGANDS; PREPARATION AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20220265643-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-08-25 | — | — | US | disclosed |
| US-20220185798-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-06-16 | — | — | US | disclosed |
| US-20220185798-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-06-16 | — | — | US | disclosed |
| US-20210346373-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-11-11 | — | — | US | disclosed |
| EP-3849963-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | The United States of America, as Represented By the Secretary, Department of Health and Human Services (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3848351-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3429993-B1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | US HEALTH (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20200291000-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-09-17 | — | — | US | disclosed |
| US-20200291000-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-09-17 | — | — | US | disclosed |
| WO-2020055725-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-03-19 | — | — | WO | disclosed |
| EP-3429993-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2019-01-23 | — | — | EP | disclosed |
| WO-2017160552-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017160552-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185798-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | DRD3, DRD2, SLC6A3 | DRD2 2/4885DRD3 1/4885HTR1A 45/4885 |
| US-20210346373-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | OPRD1, OPRK1, DRD3 | DRD2 6/4885DRD3 3/4885HTR1A 54/4885 |
| US-12162861-B2 | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | DRD3, DRD2, SLC6A3 | DRD2 2/4885DRD3 1/4885HTR1A 45/4885 |
| US-20200291000-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | DRD3, DRD2, SLC6A3 | DRD2 2/4885DRD3 1/4885HTR1A 45/4885 |
| US-12097196-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | OPRD1, OPRK1, DRD3 | DRD2 6/4885DRD3 3/4885HTR1A 54/4885 |
| US-20240408084-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | DRD3, OPRD1, DRD2 | DRD2 3/4885DRD3 1/4885HTR1A 65/4885 |
| US-20220265643-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | OPRD1, OPRK1, DRD3 | DRD2 6/4885DRD3 3/4885HTR1A 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.